MedWatch

Novo Nordisk enters USD 6.3m legal settlement in US

Allegations that Novo Nordisk had breached the US Trade Agreement Act of 1979 have been resolved in a settlement, though the Danish pharmaceutical company admits no wrongdoing.

Photo: Novo Nordisk / PR

Novo Nordisk has entered a settlement in the US, paying USD 6.3m according to MarketWire.

The settlement resolves allegations by the US Department of Justice, the DOJ, concerning some Novo Nordisk products marketed in the US that were reportedly produced in blacklisted countries, meaning they were in violation of the US Trade Agreement Act of 1979.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs